Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | PARG | Q86W56 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PRF1 | P14222 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250778 | 0.82 | KMT2A (0.46) | KMT2AMAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL10016535 | 0.81 | SMN1; SMN2 (1.00) | KMT2AMAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL23345426 | 0.80 | KMT2A (0.77) | KMT2AMAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL12093538 | 0.80 | KMT2A (0.71) | KMT2AMAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL7145890 | 0.80 | LMNA (0.77) | KMT2AMAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL7141554 | 0.79 | MAPT (0.74) | KMT2AMAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL265040 | 0.79 | MAPT (0.69) | KMT2AMAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL2018411 | 0.79 | LMNA (0.69) | KMT2AMAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL29973441 | 0.79 | LMNA (0.69) | KMT2AMAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL9917388 | 0.79 | LMNA (0.69) | KMT2AMAPTSMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370521-B1 | FORMANILIDE DERIVATIVES AS BETA2-ADRENORECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-7045658-B2 | prophylaxis and treatment of respiratory diseases; phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2006-05-16 | — | — | US | disclosed |
| US-20040157830-A1 | Formailide derivatives as beta2-adrenoreceptor agonists | GLAXO GROUP LIMITED (GB) | 2004-08-12 | — | — | US | disclosed |
| EP-1370521-A1 | FORMANILIDE DERIVATIVES AS BETA2-ADRENORECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002076933-A1 | FORMAILIDE DERIVATIVES AS BETA2-ADRENORECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157830-A1 | Formailide derivatives as beta2-adrenoreceptor agonists | ADRB2, ADRB1, ADRA2A | KMT2A 3907/4885MAPT 1725/4885SMN1; SMN2 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.